PDF herunterladen
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(08): 539-554
DOI: 10.1590/0004-282X20180078
Consensus

Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis

Consenso Brasileiro para o Tratamento da Esclerose Múltipla: Academia Brasileira de Neurologia e Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla
Vanessa Daccach Marques
1   Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto SP, Brasil;
,
Giordani Rodrigues dos Passos
2   Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre RS, Brasil;
,
Maria Fernanda Mendes
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, São Paulo SP, Brasil;
,
Dagoberto Callegaro
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, São Paulo SP, Brasil;
,
Marco Aurélio Lana-Peixoto
4   Universidade Federal de Minas Gerais, Centro de Investigação em Esclerose Múltipla de Minas Gerais, Belo Horizonte MG, Brasil;
,
Elizabeth Regina Comini-Frota
5   Universidade José do Rosário Vellano, Belo Horizonte MG, Brasil;
,
Cláudia Cristina Ferreira Vasconcelos
6   Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro RJ, Brasil;
,
Douglas Kazutoshi Sato
2   Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre RS, Brasil;
,
Maria Lúcia Brito Ferreira
7   Hospital da Restauração, Recife PE, Brasil;
,
Mçnica Koncke Fiuza Parolin
8   Clínica Gonçalves Dias, Curitiba PR, Brasil;
,
Alfredo Damasceno
9   Universidade de Campinas, Campinas SP, Brasil;
,
Anderson Kuntz Grzesiuk
10   Clínica Privada, Cuiabá MT, Brasil;
,
André Muniz
11   Hospital São Rafael, Salvador BA, Brasil;
,
André Palma da Cunha Matta
12   Universidade Federal Fluminense, Niterói RJ, Brasil;
,
Bianca Etelvina Santos de Oliveira
13   Fundação Centro Integrado de Apoio ao Portador de Deficiência, João Pessoa PB, Brazil;
,
Carlos Bernardo Tauil
14   Universidade de Brasília, Brasília DF, Brasil;
15   Universidade Católica de Brasília, Brasília DF, Brasil;
,
Damacio Ramón Kaimen Maciel
16   Santa Casa de Misericórdia de Londrina, Londrina PR, Brasil;
,
Denise Sisteroli Diniz
17   Faculdade de Medicina da Universidade Federal de Goiás, Goiânia GO, Brasil;
,
Eber Castro Corrêa
18   Clínica de Neurologia e Endocrinologia, Brasília DF, Brasil;
,
Fernando Coronetti
19   Universidade Estadual Paulista, São Paulo SP, Brasil;
,
Frederico M. H. Jorge
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, São Paulo SP, Brasil;
,
Henry Koiti Sato
20   Instituto de Neurologia de Curitiba, Curitiba PR, Brasil;
,
Marcus Vinícius Magno Gonçalves
21   Universidade da Região de Joinville, Joinville SC, Brasil;
,
Nise Alessandra de C. Sousa
22   Universidade Federal do Amazonas, Hospital Universitário Getúlio Vargas, Manaus AM, Brazil;
,
Osvaldo J. M. Nascimento
12   Universidade Federal Fluminense, Niterói RJ, Brasil;
,
Paulo Diniz da Gama
23   Pontifícia Universidade Católica de São Paulo, Sorocaba SP, Brasil;
,
Renan Domingues
24   Senne Líquor Diagnóstico, São Paulo SP, Brasil.
25   Hospital Cruz Azul, São Paulo SP, Brasil;
26   Faculdade São Leopoldo Mandic, Campinas SP, Brasil;
,
Renata Faria Simm
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, São Paulo SP, Brasil;
,
Rodrigo Barbosa Thomaz
27   Hospital Israelita Albert Einstein, São Paulo SP, Brasil;
,
Rogério de Rizo Morales
28   Universidade Federal de Uberlândia, Uberlândia MG, Brasil;
,
Ronaldo Maciel Dias
29   Hospital de Base do Distrito Federal, Brasília DF, Brasil;
,
Samira dos Apóstolos-Pereira
3   Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, São Paulo SP, Brasil;
,
Suzana Costa Nunes Machado
30   Imperial Hospital de Caridade, Florianópolis SC, Brasil;
,
Thiago de Faria Junqueira
31   Escola Bahiana de Medicina e Saúde Pública, Salvador BA, Brasil.
,
Jefferson Becker
2   Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre RS, Brasil;
12   Universidade Federal Fluminense, Niterói RJ, Brasil;
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

ABSTRACT

The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.

RESUMO

O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e personalizados, mas a escolha e o manejo das terapias modificadoras da doença (TMDs) tem se tornado cada vez mais complexos. Neste contexto, especialistas do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla e do Departamento Científico de Neuroimunologia da Academia Brasileira de Neurologia reuniram-se para estabelecer este Consenso Brasileiro para o Tratamento da EM, baseados no entendimento de que neurologistas devem ter a possibilidade de prescrever TMDs para EM de acordo com o que é melhor para cada paciente, com base em evidências e práticas atualizadas. Por meio deste documento, propomos recomendações práticas para o tratamento da EM, com foco principal na escolha e no manejo das TMDs, e revisamos os argumentos que embasam as estratégias de tratamento na EM.

Keywords:

multiple sclerosis - drug therapy - consensus

Palavras-chave:

esclerose múltipla - tratamento farmacológico - consenso

APPENDIX



Publikationsverlauf

Eingereicht: 17. März 2018

Angenommen: 16. Mai 2018

Artikel online veröffentlicht:
23. August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Multiple Sclerosis International Federation. Atlas of MS 2013: mapping multiple sclerosis around the world. London: Multiple Sclerosis International Federation; 2013.
  • 2 Comi G, Radaelli M, Soelberg Sørensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017 Apr;389(10076):1347-56. https://doi.org/10.1016/S0140-6736(16)32388-1
  • 3 Ministério da Saúde (Brasil). Secretaria de Atenção à Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria Conjunta Nº 10, de 2 de abril de 2018. Aprova o protocolo clínico e diretrizes trapêuticas da esclerose múltipla. Brasília, DF, 2018 [accessed 2018 May 8] Available from: http://portalarquivos2.saude.gov.br/images/pdf/2018/abril/09/PORTARIA-CONJUNTA-N-10-ESCLEROSE-MULTIPLA.09.04.2018.pdf
  • 4 Tilbery CP, Moreira MA, Mendes MF, Lana-Peixoto MA. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus]. Arq Neuropsiquiatr. 2000 Sep;58 3A:769-76. Portuguese. https://doi.org/10.1590/S0004-282X220180078400030
  • 5 Callegaro D, Lana-Peixoto MA, Moreira MA, Marchiori PE, Bacheschi LA, Arruda WO et al. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: I. The evidences for the use of immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation]. Arq Neuropsiquiatr. 2002 Sep;60 3-B:869-74. Portuguese. https://doi.org/10.1590/S0004-282X2002000500035
  • 6 Moreira MA, Lana-Peixoto MA, Callegaro D, Haussen SR, Gama PD, Gabbai AA et al. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments]. Arq Neuropsiquiatr. 2002 Sep;60 3-B:875-80. Portuguese. https://doi.org/10.1590/S0004-282X2002000500036
  • 7 Lana-Peixoto MA, Callegaro D, Moreira MA, Campos GB, Marchiori PE, Gabbai AA et al. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines]. Arq Neuropsiquiatr. 2002 Sep;60 3-B:881-6. Portuguese. https://doi.org/10.1590/S0004-282X2002000500037
  • 8 Machado S. Recomendações Esclerose Múltipla - Academia Brasileira de Neurologia. São Paulo: Omnifarma; 2012.
  • 9 Comini-Frota ER, Vasconcelos CCF, Mendes MF. Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology. Arq Neuropsiquiatr. 2017 Jan;75(1):57-65. https://doi.org/10.1590/0004-282X20160185
  • 10 Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013 May;40(3):307-23. https://doi.org/10.1017/S0317167100014244
  • 11 Scolding N, Barnes D, Cader S, Chataway J, Chaudhuri A, Coles A et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015 Aug;15(4):273-9. https://doi.org/10.1136/practneurol-2015-001139
  • 12 Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018 Feb;25(2):215-37. https://doi.org/10.1111/ene.13536
  • 13 Thompson AJ, Banwell BL, Barkhof F, Carrol WM, Coetzee T, Comi G et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. https://doi.org/10.1016/S1474-4422(17)30470-2
  • 14 Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul;83(3):278-86. https://doi.org/10.1212/WNL.20180078201800780560
  • 15 Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul;138(Pt 7):1863-74. https://doi.org/10.1093/brain/awv105
  • 16 Fazekas F, Bajenaru O, Berger T, Fabjan TH, Ledinek AH, Jakab G et al. How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol. 2013 May;4:10. https://doi.org/10.3389/fneur.2013.00010
  • 17 Devonshire V, Havrdova E, Radue EW, O’Connor P, Zhang-Auberson L, Agoropoulou C et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012 May;11(5):420-8. https://doi.org/10.1016/S1474-4422(12)70056-X
  • 18 Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015 Jul;11(7):379-89. https://doi.org/10.1038/nrneurol.2015.85
  • 19 Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1192-8. https://doi.org/10.1136/jnnp-2013-304951
  • 20 Ingwersen J, Aktas O, Hartung HP. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016 Jan;13(1):47-57. https://doi.org/10.1007/s13311-015-0412-4
  • 21 Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40. https://doi.org/10.1016/j.mayocp.2013.11.002
  • 22 Vosoughi R, Freedman MS. Therapy of MS. Clin Neurol Neurosurg. 2010 Jun;112(5):365-85. https://doi.org/10.1016/j.clineuro.2010.03.010
  • 23 Balabanov P, Haas M, Elferink A, Bakchine S, Broich K. Addressing the regulatory and scientific challenges in multiple sclerosis: a statement from the EU regulators. Mult Scler. 2014 Sep;20(10):1282-7. https://doi.org/10.1177/1352458514546876
  • 24 Sorensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014 Jun;27(3):246-59. https://doi.org/10.1097/WCO.20180078201800780096
  • 25 Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. https://doi.org/10.1111/ene.12883
  • 26 Cross AH, Naismith RT. Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med. 2014 Apr;275(4):350-63. https://doi.org/10.1111/joim.12203
  • 27 Carrithers MD. Update on disease-modifying treatments for multiple sclerosis. Clin Ther. 2014 Dec;36(12):1938-45. https://doi.org/10.1016/j.clinthera.2014.08.006
  • 28 Michel L, Larochelle C, Prat A. Update on treatments in multiple sclerosis. Presse Med. 2015 Apr;44(4 Pt 2):e137-51. https://doi.org/10.1016/j.lpm.2015.02.008
  • 29 Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. J Clin Neurosci. 2014 Nov;21(11):1857-65. https://doi.org/10.1016/j.jocn.2014.01.017
  • 30 García-Merino A, Fernández O, Montalbán X, Andrés C, Oreja-Guevar C, Rodríguez-Antigüedad A et al. Documento del Grupo de Consenso de la Sociedad Española de Neurología sobre el uso de medicamentos en esclerosis múltiple. Neurología. 2013;28(6):375-8. https://doi.org/10.1016/j.nrl.2013.01.009
  • 31 Limmroth V. Treatment of relapsing-remitting multiple sclerosis: current and future algorithms. Eur Neurol. 2014;72(s1 Suppl 1):35-8. https://doi.org/10.1159/000367624
  • 32 Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R et al. Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. Neurology. 2014 Dec;83(24):2219-26. https://doi.org/10.1212/WNL.20180078201800781066
  • 33 Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol. 2016 Mar;15(3):317-31. https://doi.org/10.1016/S1474-4422(15)00313-0
  • 34 Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol. 2016 Feb;15(2):198-209. https://doi.org/10.1016/S1474-4422(15)00334-8
  • 35 Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 Jul;133(Pt 7):1900-13. https://doi.org/10.1093/brain/awq076
  • 36 Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A. B Cells in the multiple sclerosis central nervous system: trafficking and contribution to CNS-compartmentalized inflammation. Front Immunol. 2015 Dec;6:636. https://doi.org/10.3389/fimmu.2015.00636
  • 37 Pikor NB, Prat A, Bar-Or A, Gommerman JL. Meningeal tertiary lymphoid tissues and multiple sclerosis: a gathering place for diverse types of immune cells during CNS autoimmunity. Front Immunol. 2016 Jan;6:657. https://doi.org/10.3389/fimmu.2015.00657
  • 38 Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci. 2008 Nov;274(1-2):42-4. https://doi.org/10.1016/j.jns.2008.06.032
  • 39 Jokubaitis VG, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 2016 Jul;80(1):89-100. https://doi.org/10.1002/ana.24682
  • 40 Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010 Jul;133(Pt 7):1914-29. https://doi.org/10.1093/brain/awq118
  • 41 Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):67-75. https://doi.org/10.1136/jnnp-2012-304333
  • 42 Myhr KM, Riise T, Vedeler C, Nortvedt MW, Grønning R, Midgard R et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler. 2001 Feb;7(1):59-65. https://doi.org/10.1177/135245850100700110
  • 43 Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci. 1999 Oct;168(2):96-106. https://doi.org/10.1016/S0022-510X(99)00143-4
  • 44 Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003 Dec;61(11):1528-32. https://doi.org/10.1212/01.WNL.0000096175.39831.21
  • 45 Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008 Feb;255(2):280-7. https://doi.org/10.1007/s00415-008-0743-8
  • 46 Vercellino M, Romagnolo A, Mattioda A, Masera S, Piacentino C, Merola A et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand. 2009 Feb;119(2):126-30. https://doi.org/10.1111/j.1600-0404.2008.01076.x
  • 47 Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci. 2001 Aug;189(1-2):13-21. https://doi.org/10.1016/S0022-510X(01)00572-X
  • 48 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan;338(5):278-85. https://doi.org/10.1056/NEJM199801293380502
  • 49 Riise T, Grønning M, Fernández O, Lauer K, Midgard R, Minderhoud JM et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand. 1992 Mar;85(3):212-8. https://doi.org/10.1111/j.1600-0404.1992.tb04031.x
  • 50 Tremlett H, Yinshan Zhao, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008 Apr;14(3):314-24. https://doi.org/10.1177/1352458507084264
  • 51 Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011 Sep;77(13):1246-52. https://doi.org/10.1212/WNL.0b013e318230a17d
  • 52 Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malignant multiple sclerosis. Neurology. 2011 Jun;76(23):1996-2001. https://doi.org/10.1212/WNL.0b013e31821e559d
  • 53 Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler. 2012 Jan;18(1):45-54. https://doi.org/10.1177/1352458511417479
  • 54 Bermel RA, You X, Foulds P, Hyde R, Simon JH, Fisher E et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol. 2013 Jan;73(1):95-103. https://doi.org/10.1002/ana.23758
  • 55 Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N et al. Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients. Mult. Scler. J. 2008;14(4):479-84. https://doi.org/10.1177/1352458507085555
  • 56 Losseff NA, Miller DH, Kidd D, Thompson AJ. The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis: preliminary results. Mult Scler. 2001 Feb;7(1):23-5.
  • 57 Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008 Mar;131(Pt 3):808-17. https://doi.org/10.1093/brain/awm329
  • 58 Maghzi AH, Revirajan N, Julian LJ, Spain R, Mowry EM, Liu S et al. Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. Mult Scler Relat Disord. 2014 Nov;3(6):720-7. https://doi.org/10.1016/j.msard.2014.07.003
  • 59 Sormani MP, Arnold DL, De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):43-9. https://doi.org/10.1002/ana.24018
  • 60 De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001 Jan;58(1):65-70. https://doi.org/10.1001/archneur.58.1.65 PMID:11176938
  • 61 von Gumberz J, Mahmoudi M, Young K, Schippling S, Martin R, Heesen C et al. Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting. PeerJ. 2016 Sep;4:e2442. https://doi.org/10.7717/peerj.2442
  • 62 Kalincik T, Vaneckova M, Tyblova M, Krasensky J, Seidl Z, Havrdova E, et al. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One. 2012;7(11):e50101. https://doi.org/10.1371/journal.pone.0050101
  • 63 Rocca MA, Comi G, Filippi M. The role of T1-weighted derived measures of neurodegeneration for assessing disability progression in multiple sclerosis. Front Neurol. 2017 Sep;8:433. https://doi.org/10.3389/fneur.2017.00433
  • 64 Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan;253(1):98-108. https://doi.org/10.1007/s00415-005-0934-5
  • 65 Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000 Sep;343(13):898-904. https://doi.org/10.1056/NEJM200009283431301
  • 66 Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001 May;357(9268):1576-82. https://doi.org/10.1016/S0140-6736(00)04725-5
  • 67 Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006 Oct;67(7):1242-9. https://doi.org/10.1212/01.wnl.0000237641.33768.8d
  • 68 Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct;374(9700):1503-11. https://doi.org/10.1016/S0140-6736(09)61259-9
  • 69 Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012 Jan;11(1):33-41. https://doi.org/10.1016/S1474-4422(11)70262-9
  • 70 Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Oct;13(10):977-86. https://doi.org/10.1016/S1474-4422(14)70191-7
  • 71 Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord. 2014 Mar;3(2):147-55. https://doi.org/10.1016/j.msard.2013.07.001
  • 72 Stewart T, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, et al. Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler. 2017 Feb;23(2):266-76. https://doi.org/10.1177/1352458516643392
  • 73 Damasceno A, Von Glehn F, Brandão CO, Damasceno BP, Cendes F. Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci. 2013 Jan;324(1-2):29-33. https://doi.org/10.1016/j.jns.2012.09.020
  • 74 Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec;63(12):1686-91. https://doi.org/10.1001/archneur.63.12.1686
  • 75 Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):400-3. https://doi.org/10.1136/jnnp.2008.157305
  • 76 Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G et al. Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler. 2014 Oct;20(11):1511-22. https://doi.org/10.1177/1352458514528762
  • 77 Deen S, Bacchetti P, High A, Waubant E. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1190-3. https://doi.org/10.1136/jnnp.2007.136440
  • 78 Capra R, Cordioli C, Rasia S, Gallo F, Signori A, Sormani MP. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler. 2017 Nov;23(13):1757-61. https://doi.org/10.1177/1352458516687402
  • 79 Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008 Sep;29(S2 Suppl 2):S253-5. https://doi.org/10.1007/s10072-008-0954-x
  • 80 Fenu G, Lorefice L, Frau F, Coghe GC, Marrosu MG, Cocco E. Induction and escalation therapies in multiple sclerosis. Antiinflamm Antiallergy Agents Med Chem. 2015;14(1):26-34. https://doi.org/10.2174/1871523014666150504122220
  • 81 Wiendl H. Cladribine - an old newcomer for pulsed immune reconstitution in MS. Nat Rev Neurol. 2017 Oct;13(10):573-4. https://doi.org/10.1038/nrneurol.2017.119
  • 82 Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014 Mar;13(3):257-67. https://doi.org/10.1016/S1474-4422(14)70005-5
  • 83 Montalban X, Cohen B, Leist T, et al. Efficacy of Cladribine Tablets as add-on to IFN-beta therapy in patients with active relapsing MS: final results from the Phase II ONWARD Study (P3.029). Neurology. 2016;86(16 Supplement).
  • 84 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al.; The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996 Mar;39(3):285-94. https://doi.org/10.1002/ana.410390304
  • 85 PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998 Nov;352(9139):1498-504. https://doi.org/10.1016/S0140-6736(98)03334-0
  • 86 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993 Apr;43(4):655-61. https://doi.org/10.1212/WNL.43.4.655
  • 87 Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al; The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995 Jul;45(7):1268-76. https://doi.org/10.1212/WNL.45.7.1268
  • 88 Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013 Jun;73(6):705-13. https://doi.org/10.1002/ana.23938
  • 89 Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. https://doi.org/10.1016/S1474-4422(14)70068-7
  • 90 Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012 Sep;367(12):1098-107. https://doi.org/10.1056/NEJMoa1114287
  • 91 Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep;367(12):1087-97. https://doi.org/10.1056/NEJMoa1206328
  • 92 O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct;365(14):1293-303. https://doi.org/10.1056/NEJMoa1014656
  • 93 Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson T, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Mar;13(3):247-56. https://doi.org/10.1016/S1474-4422(13)70308-9
  • 94 Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov;380(9856):1819-28. https://doi.org/10.1016/S0140-6736(12)61769-3
  • 95 Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov;380(9856):1829-39. https://doi.org/10.1016/S0140-6736(12)61768-1
  • 96 Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb;362(5):416-26. https://doi.org/10.1056/NEJMoa0902533
  • 97 Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb;362(5):387-401. https://doi.org/10.1056/NEJMoa0909494
  • 98 Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun;13(6):545-56. https://doi.org/10.1016/S1474-4422(14)70049-3
  • 99 Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar;354(9):899-910. https://doi.org/10.1056/NEJMoa044397
  • 100 Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017 Jan;376(3):221-34. https://doi.org/10.1056/NEJMoa1601277
  • 101 Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun;381(9884):2167-75. https://doi.org/10.1016/S0140-6736(12)62190-4
  • 102 Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2015 Oct;373(15):1418-28. https://doi.org/10.1056/NEJMoa1501481
  • 103 European Medicines Agency. EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders. 2018 [accessed on 2018 Mar 14] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2018/03/WC500244890.pdf
  • 104 Biogen. Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis. 2018 [accessed on 2018 Mar 14]. Available from: http://media.biogen.com/press-release/autoimmune-diseases/biogenand-abbvie-announce-voluntaryworldwide-withdrawal-marketi
  • 105 Killian JM, Bressler RB, Armstrong RM, Huston DP. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol. 1988 Jan;45(1):27-30. https://doi.org/10.1001/archneur.1988.00520250033014
  • 106 Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet. 1997 Mar;349(9052):589-93. https://doi.org/10.1016/S0140-6736(96)09377-4
  • 107 Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002 Dec;360(9350):2018-25. https://doi.org/10.1016/S0140-6736(02)12023-X
  • 108 Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 Feb;358(7):676-88. https://doi.org/10.1056/NEJMoa0706383
  • 109 Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015 Mar;84(10):981-8. https://doi.org/10.1212/WNL.20180078201800781329
  • 110 European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491-7. https://doi.org/10.1016/S0140-6736(98)10039-9
  • 111 Kappos L, Bar-Or A, Cree BA, Fox RJ, Giovannoni G, Gold R et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar;391(10127):1263-73. https://doi.org/10.1016/S0140-6736(18)30475-6
  • 112 Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan;376(3):209-20. https://doi.org/10.1056/NEJMoa1606468
  • 113 Ghezzi A, Amato MP, Makhani N, Shreiner T, Gärtner J, Tenembaum S. Pediatric multiple sclerosis: conventional first-line treatment and general management. Neurology. 2016 Aug;87(9 Suppl 2):S97-102. https://doi.org/10.1212/WNL.20180078201800782823
  • 114 Chitnis T. PARADIGMS: a randomised double-blind study of fingolimod versus interferon β-1a in paediatric multiple sclerosis. ECTRIMS Online Library. 2017 Oct 28;202640.
  • 115 Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG. Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol. 2016 Aug;15(9):967-81. https://doi.org/10.1016/S1474-4422(16)30043-6
  • 116 Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017 May;14:72-9. https://doi.org/10.1016/j.msard.2017.04.003
  • 117 Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disorder. 2015 Sep;8(5):233-8. https://doi.org/10.1177/1756285615594575
  • 118 Correale J, Ysrraelit MC, Fiol MP. Benign multiple sclerosis: does it exist? Curr Neurol Neurosci Rep. 2012 Oct;12(5):601-9. https://doi.org/10.1007/s11910-012-0292-5
  • 119 Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics. 2013 Jan;10(1):97-105. https://doi.org/10.1007/s13311-012-0160-7
  • 120 Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, et al; COPOUSEP investigators; West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015 Sep;386(9997):974-81. https://doi.org/10.1016/S0140-6736(15)61137-0
  • 121 National Clinical Advisory Board, National Multiple Sclerosis Society. Recommendations Regarding Corticosteroids in the Management of Multiple Sclerosis. US Neurol. 2008;4(1):22. https://doi.org/10.17925/USN.2008.04.01.22.
  • 122 Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. In: Goodin DS, editor. Handbook of Clinical Neurology. [S. l.}: Elsevier; 2014. p. 513-62.
  • 123 Shoemaker TJ, Mowry EM. A review of vitamin D supplementation as disease-modifying therapy. Mult Scler. 2018 Jan;24(1):6-11. https://doi.org/10.1177/1352458517738131
  • 124 Brum DG, Comini-Frota ER, Vasconcelos CC, Dias-Tosta E. Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology. Arq Neuropsiquiatr. 2014 Feb;72(2):152-6. https://doi.org/10.1590/0004-282X20130252
  • 125 Brochet B, Deloire MSA, Perez P, Loock T, Baschet L, Debouverie M et al; PROMESS study investigators. Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLOS One. 2017 Jan; 12(1):e0168834. https://doi.org/10.1371/journal.pone.0168834